Brief: Annovis Bio Inc Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing
U.S. STOCKS ON THE MOVE-Tesla, Microsoft, BlackBerry
U.S. STOCKS ON THE MOVE-Netfilx, DuPont, Baker Hughes
U.S. STOCKS ON THE MOVE-Gold miners, TE Connectivity, Amphenol
Brief: Annovis Bio Refines Timeline For Parkinson’S Phase Iii Study Data Announcement
Annovis Bio falls on delayed study results for Parkinson's therapy
Brief: Annovis Bio Announces Last Patient Last Visit In The Phase Iii Study Of Buntanetap In Parkinson’S Disease
U.S. STOCKS ON THE MOVE-DR Horton, Federal Realty, RedHill Biopharma
Annovis Bio up on full enrollment in Alzheimer's drug trial
Brief: Annovis Bio Announces Full Enrollment Of Its Phase II/III Alzheimer’S Disease Trial
Annovis Bio Inc expected to post a loss of $1.09 a share - Earnings Preview
Brief: Annovis Bio Announces Pricing Of $7.5 Million Public Offering
Annovis Bio Inc reports results for the quarter ended in June - Earnings Summary
Annovis Bio Inc expected to post a loss of $1.14 a share - Earnings Preview
Factbox: Companies in Alzheimer's race after US nod for Eisai/Biogen drug
Brief: Annovis Bio Inc Announces Filing Of Patent
U.S. STOCKS ON THE MOVE-Constellation Energy, Cactus, Cardinal Health
U.S. STOCKS ON THE MOVE-CureVac, Aclarion, Baosheng Media
U.S. STOCKS ON THE MOVE-Carvana, Annovis Bio, Aclarion